Pittsburgh, PANCT06666439Now EnrollingIRB Ready

Metastatic Invasive Lobular Carcinoma (mILC) Clinical Trial in Pittsburgh, PA

Access cutting-edge metastatic invasive lobular carcinoma (milc) treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by Julia Foldi

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access metastatic invasive lobular carcinoma (milc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic invasive lobular carcinoma (milc) treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this metastatic invasive lobular carcinoma (milc) clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Metastatic Invasive Lobular Carcinoma (mILC) Study in Pittsburgh

The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.

Sponsor: Julia Foldi

Who Can Participate

Inclusion Criteria

Signed informed consent
Patients must have histologically or cytologically confirmed invasive lobular breast cancer that is ER+ (\> 1% staining) and HER2-negative as per ASCO/CAP guidelines with radiographical or clinical evidence of metastatic disease
Lobular histology as assessed on either tissue collected from a metastatic lesion or from the patient's primary breast tumor (in case of recurrent metastatic disease)
Patients with mixed ductal/lobular (NST/ILC) tumors are eligible to participate (with the ultimate goal to evaluate 20 patients with pure ILC)
Patients must have tumor tissue available for whole exome sequencing for Signatera assay design
Prior therapies:
Patients must not have received any therapy in the metastatic setting
Patients could have received adjuvant therapy as indicated for their primary breast cancer
Age ≥ 18 years
Patients may be pre- or post-menopausal.

Exclusion Criteria

Stage I-III breast cancer
Lack of lobular histology on tumor tissue biopsy
Other active cancer (previously treated cancer with no current evidence of disease is allowed)
ctDNA assay development is unattainable due to insufficient tumor tissue or sequencing failure

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT06666439) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Invasive Lobular Carcinoma (mILC) Treatment Options in Pittsburgh, PA

If you're searching for metastatic invasive lobular carcinoma (milc) treatment options in Pittsburgh, PA, this clinical trial (NCT06666439) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic invasive lobular carcinoma (milc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic invasive lobular carcinoma (milc) clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Pittsburgh, PA

See all heart attack clinical trials recruiting in Pittsburgh — not just this study.

Browse Heart Attack Trials in Pittsburgh →

Browse More Trials by Condition

Heart Attack TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA